E
EIT Pharma
Biotech & Life Sciences · Kirkland, United States · Founded 2025
Therapies for serious and life-threatening viral diseases. MoreLess
EIT Pharma, Inc. is a Kirkland, Washington-based biotechnology company focused on developing therapies for serious viral and infectious diseases with significant unmet medical need. Its lead candidate is lonafarnib (Jitixib), a first-in-class oral farnesyltransferase inhibitor being developed for chronic hepatitis D (CHD), supported by the Phase 3 D-LIVR study — the largest clinical trial conducted to date in CHD. Lonafarnib has received FDA Breakthrough Therapy, Fast Track and Orphan Drug designations, and its New Drug Application was accepted for FDA review in August 2026. The company is also advancing peginterferon lambda-1a (lambda) for chronic hepatitis D and severe acute viral respiratory tract infections.
Company overview
EIT Pharma company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2025
- Headquarters
- Kirkland, United States
- Employees
- 6
- Open positions
- None listed
- Dealroom signal
- 25.0
Valuation & funding
EIT Pharma funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Aug 2026 | $35M | $140M | Good Ventures · Propel Bio Partners | ↗ |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 6 |
Growth signals
EIT Pharma website traffic
Latest recorded traffic for EIT Pharma is 1.8K monthly website visits.
Comparisons
EIT Pharma compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 R1 TherapeuticsPharmaceutical therapies targeting neurological, metabolic and infectious conditions |
Temecula, United States | Operational | 16 | $78M | $310M |
 AkigaiRepurposed oncology drugs for neuropathic pain treatment |
Oslo, Norway | Operational | |||
 IstessoDeveloping adaptive tissue-repair drugs for chronic diseases |
London, United Kingdom | Operational | |||
 AbivaxStimulation of the immune system for the complete elimination of viral diseases using its unique antiviral platform technologies |
Paris, France | Operational | |||
 Dimicare BiotechPrecision antibiotics for multidrug-resistant pathogens. |
Nice, France | Operational | |||
 AllRock BioTherapies for rare cardiopulmonary and fibrotic diseases |
Natick, United States | Operational | |||
 Otsuka PharmaceuticalGlobal leader in pharmaceuticals and health-enhancing nutraceutical products |
Tokyo, Japan | Operational | |||
 Pharmotech SAPhytopharma R&D for antibiotic-resistant bacteria applications. |
Plan-les-Ouates, Switzerland | Operational |
Talent graph
EIT Pharma's talent
Source: Dealroom Talent Intelligence.
Investors
2 investors on EIT Pharma's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where EIT Pharma has talent and traffic
team presence
In the news
Latest news about EIT Pharma
Recent press, funding announcements, and product moves mentioning EIT Pharma — open to read from the original sources.
Market sentiment
What the market is saying about EIT Pharma
An AI-synthesized read of the highest-engagement posts about EIT Pharma on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See EIT Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.